08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Egalet, Shionogi deal

Shionogi terminated a 2013 deal to develop and commercialize oral abuse-deterrent hydrocodone opioid products using Egalet’s drug delivery technology, including S-718632 . Egalet said the termination was due to Shionogi’s reprioritization of its internal development...
02:09 , Dec 5, 2015 |  BC Extra  |  Company News

Shionogi terminates pain deal with Egalet

Egalet Corp. (NASDAQ:EGLT) said it would regain rights to abuse-deterrent pain candidate AD ER hydrocodone ( S-718632 ) after Shionogi & Co. Ltd. (Tokyo:4507) terminated the companies' 2013 deal to develop and commercialize abuse-deterrent analgesics....
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Egalet Corp, Shionogi deal

Egalet received a $10 million milestone payment from Shionogi under the companies’ 2013 deal to develop and commercialize oral abuse-deterrent hydrocodone opioid products using Egalet’s drug delivery technology. The payment was triggered after an IND...